SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-047833
Filing Date
2021-04-08
Accepted
2021-04-08 08:00:34
Documents
8
Period of Report
2021-05-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm212433-2_def14a.htm DEF 14A 1997309
2 GRAPHIC lg_adaptimmune-4clr.jpg GRAPHIC 38136
3 GRAPHIC tm212433d2-pc_ceobwlr.jpg GRAPHIC 41609
4 GRAPHIC tm212433d2-pc_executbwlr.jpg GRAPHIC 55419
5 GRAPHIC tm212433d2-lc_perfor4clr.jpg GRAPHIC 144591
6 GRAPHIC tm212433d2-bc_executive4clr.jpg GRAPHIC 120321
7 GRAPHIC tm212433d2-proxy_1pagebw.jpg GRAPHIC 797521
8 GRAPHIC tm212433d2-proxy_2pagebw.jpg GRAPHIC 621425
  Complete submission text file 0001104659-21-047833.txt   4498297
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37368 | Film No.: 21813809
SIC: 2836 Biological Products, (No Diagnostic Substances)